Liz Highleyman

New site-agnostic therapy shrank tumors in people with a variety of cancers with NTRK gene fusions as well as ROS1-positive lung cancer.

FDA warns that drinking Miracle Mineral Solution and similar products is potentially life-threatening.

The program will pay 65% of the cost of providing the custom-made immunotherapy.

NKTR-214 plus Opdivo has been granted an FDA breakthrough therapy designation for advanced melanoma.

The androgen receptor inhibitor delayed cancer metastasis in a late-stage clinical trial.

Some of the most common and deadly cancers receive little attention and resources.

Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.

People with HIV had low rates of complications similar to those of HIV-negative patients.

The novel immune-enhancing antibody delays disease progression, especially in people with a common genetic variant.

Study sheds light on the inverse association between cancer and Alzheimer’s disease.

First nuclear export inhibitor gets the nod for patients lacking treatment options.

Widespread vaccination could potentially eliminate cervical, anal, oral and other HPV-related cancers.

People living with HIV are also facing cancer as they age.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

RET inhibitor shrank tumors in more than half of people with non-small-cell lung cancer and aggressive thyroid cancer.